(VIANEWS) – SANOFI (SAN.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| SANOFI (SAN.PA) | €99.58 | 3.57% | 12.07% |
| MEDISTIM (MEDI.OL) | kr219.00 | 1.96% | 31.89% |
| EUROFINS SCIENT. (ERF.PA) | €56.30 | 1.83% | 9.12% |
| UCB (UCB.BR) | €83.84 | 1.61% | 3.7% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. SANOFI (SAN.PA)
3.57% Forward Dividend Yield and 12.07% Return On Equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.85.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.54. Meaning, the purchaser of the share is investing €14.54 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.07%.
Moving Average
SANOFI’s worth is above its 50-day moving average of €97.02 and higher than its 200-day moving average of €94.51.
Volatility
SANOFI’s last week, last month’s, and last quarter’s current intraday variation average was 0.52%, 0.25%, and 0.93%.
SANOFI’s highest amplitude of average volatility was 0.68% (last week), 0.70% (last month), and 0.93% (last quarter).
More news about SANOFI.
2. MEDISTIM (MEDI.OL)
1.96% Forward Dividend Yield and 31.89% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.41.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 34.17. Meaning, the purchaser of the share is investing kr34.17 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr219.00 at 17:30 EST, way under its 52-week high of kr312.50 and way higher than its 52-week low of kr184.80.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 11.1% and a drop 6.7% for the next.
Volatility
MEDISTIM’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.07%, a negative 0.68%, and a positive 2.33%.
MEDISTIM’s highest amplitude of average volatility was 2.00% (last week), 3.02% (last month), and 2.33% (last quarter).
More news about MEDISTIM.
3. EUROFINS SCIENT. (ERF.PA)
1.83% Forward Dividend Yield and 9.12% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.69. Meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 4, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1.83%.
Moving Average
EUROFINS SCIENT.’s worth is below its 50-day moving average of €57.86 and below its 200-day moving average of €62.10.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUROFINS SCIENT.’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for EUROFINS SCIENT. is 29756 which is 91.66% below its average volume of 357001.
More news about EUROFINS SCIENT..
4. UCB (UCB.BR)
1.61% Forward Dividend Yield and 3.7% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.7.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 49.32. Meaning, the purchaser of the share is investing €49.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.7%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.8%, now sitting on 5.11B for the twelve trailing months.
Moving Average
UCB’s worth is higher than its 50-day moving average of €80.97 and above its 200-day moving average of €80.36.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 28, 2023, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.61%.
Volume
Today’s last reported volume for UCB is 63856 which is 58.16% below its average volume of 152633.
More news about UCB.
